DiaMedica Therapeutics Provides Update on Fetal Growth Restriction Key Opinion Leader Webinar

DiaMedica Therapeutics (DMAC) rescheduled its DM199 fetal growth restriction webinar from October 23 to November 24, 2026, at 8:00 a.m. Eastern Time.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction now Scheduled for November 24, 2026
• Event to Include Results from First Two Phase 2 Early-Onset FGR Trial Cohorts

MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction (FGR) and acute ischemic stroke, today announced that its virtual key opinion leader (KOL) event, previously scheduled for October 23, 2026, will now be held on Tuesday, November 24, 2026, at 8:00am Eastern Time.

The new date will allow the Company to expand the presentation to include preliminary, interim topline results from the second cohort of the investigator-sponsored Phase 2 early-onset FGR trial, in addition to results from the first cohort. The event will cover FGR and the therapeutic rationale for evaluating DM199 (rinvecalinase alfa) as a potential treatment for FGR.

Webinar Panel and Event Details

The webinar will feature Professor Catherine Cluver, MD, PhD (Stellenbosch University), Professor Stephen Tong, MBBS, PhD (The University of Melbourne), Professor Susan Walker, AO, MBBS, MD (The University of Melbourne), and Professor Andrew Shennan, OBE, MBBS, MD (King’s College London). The experts will discuss the FGR disease state and current treatment landscape, the role of placental insufficiency and impaired uteroplacental blood flow, the clinical rationale for DM199 as a potential treatment option for FGR, and interim safety and clinical findings from the first six participants treated in the Phase 2 early-onset FGR trial.

Dr. Cluver, the trial Principal Investigator, will review the trial design and present safety, tolerability and preliminary first and second cohort results. The panel will discuss the clinical relevance of key measures being evaluated in the trial, and the interim findings in the context of early-onset FGR.

A live question-and-answer session will follow the formal presentations.

Event Details

Date	Tuesday, November 24, 2026
Time	8:00 AM EST / 7:00 AM CST
Registration	https://lifescievents.com/event/djv5u8p/

About Professor Catherine Cluver

Professor Catherine Cluver is a maternal-fetal medicine specialist who founded and leads the Preeclampsia Research Unit at Tygerberg Hospital, Stellenbosch University, South Africa. Dr. Cluver has completed multiple preeclampsia treatment trials assessing novel therapies and curates one of the largest preeclampsia biobanks. She has published extensively in maternal-fetal medicine, including work in The Lancet and BMJ. Dr. Cluver is the Principal Investigator of the ongoing investigator-sponsored Phase 2 trial evaluating DM199 in preeclampsia and fetal growth restriction at Tygerberg Hospital.

About Professor Stephen Tong

Professor Stephen Tong is an obstetrician-scientist at the University of Melbourne and Mercy Hospital for Women with a strong focus on translational research and the development of therapeutics for major pregnancy complications. He has played a leading role in advancing multiple therapeutic concepts from laboratory research into Phase 1 through Phase 3 clinical trials. Professor Tong has authored more than 300 scientific publications, including more than 100 on preeclampsia, with research published in journals including Nature, The Lancet, BMJ and Nature Communications.

About Professor Susan Walker

Professor Susan Walker is the Sheila Handbury Chair of Maternal Fetal Medicine, Head of the Department of Obstetrics, Gynaecology and Newborn Health at the University of Melbourne, and Divisional Chair of Perinatal Medicine at Mercy Hospital for Women. Her clinical and research program focuses on improving the detection and treatment of fetal growth restriction and preeclampsia. Professor Walker has authored more than 290 publications, including work in The Lancet, New England Journal of Medicine and BMJ.

About Professor Andrew Shennan

Andrew Shennan is Professor of Obstetrics at King’s College London, based at St. Thomas’ Hospital and specializes in clinical trials and the management of high-risk pregnancy. His research focuses on the prediction and prevention of preterm birth and preeclampsia, as well as reducing maternal and perinatal mortality. Professor Shennan has published more than 700 peer-reviewed research reports and has held leadership roles including Chair of the FIGO Preterm Birth Committee and Chair of Action on Pre-eclampsia UK. He also maintains an active clinical practice, including management of high-risk obstetric patients and a specialist preterm birth surveillance clinic.

About the Phase 2 Investigator-Sponsored Fetal Growth Restriction Trial

The Phase 2 study is the third part of an open-label, single center, single-arm, safety and pharmacodynamic, proof-of-concept, investigator-sponsored trial of DM199 for the treatment of pregnancy complications currently being conducted at the Tygerberg Hospital in Cape Town, South Africa.

This part of the trial is evaluating repeated SC dosing in up to 30 early-onset FGR subjects until delivery, using up to three dose levels initially based on Part 1a data; enrollment commenced in June 2026, and the first two cohorts of 12 participants has been enrolled. Dosing levels are at 5, 10 and up to 15 µg/kg. The dose for the third cohort will be between 1 and 15 µg/kg based on results from the first two cohorts.

About Fetal Growth Restriction

Fetal growth restriction (FGR) occurs when a fetus fails to reach its genetically determined growth potential in the womb, most commonly due to placental insufficiency. FGR affects an estimated 10% of pregnancies worldwide and is associated with significantly increased risks of stillbirth, preterm birth, and neonatal morbidity, as well as long-term neurodevelopmental, cardiovascular, and metabolic complications. In severe, early-onset cases, FGR often necessitates delivery before 32 weeks of gestation, when the risks of prematurity must be weighed against the dangers of continued growth restriction in utero. For further details, see the recently released white paper, “The Potential of DM199 to Treat Fetal Growth Restriction”.

About DM199 (rinvecalinase alfa)

DM199 is a recombinant form of human tissue kallikrein-1 (rhKLK1). KLK1 is a serine protease enzyme that plays an important role in in vascular regulation through the kallikrein-kinin system, activating downstream pathways that increase the production and release of nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factor.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on preeclampsia, fetal growth restriction and acute ischemic stroke. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases. For more information visit the Company’s website at www.diamedica.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and forward-looking information that are based on the beliefs of management and reflect management’s current expectations. When used in this press release, the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” or “would,” the negative of these words or such variations thereon or comparable terminology and the use of future dates are intended to identify forward-looking statements and information. The forward-looking statements and information in this press release include statements regarding the timing and key opinion leader participation of the upcoming webinar on DM199 for fetal growth restriction. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Applicable risks and uncertainties include, among others, risks and uncertainties relating to the timing and outcomes of non-clinical studies; risks and uncertainties relating to the timing of studies and trials;; and the risks identified under the heading “Risk Factors” in DiaMedica’s annual report on Form 10-K for the fiscal year ended December 31, 2025 filed with the U.S. Securities and Exchange Commission (SEC) and subsequent SEC reports, including our most recent quarterly report on Form 10-Q. The forward-looking information contained in this press release represents the expectations of DiaMedica as of the date of this press release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While DiaMedica may elect to, it does not undertake to update this information at any particular time except as required in accordance with applicable laws.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261019862168/en/

Scott Kellen
Chief Financial Officer
Phone: (763) 496-5118
skellen@diamedica.com

For Investor Inquiries:
Mike Moyer
Managing Director, LifeSci Advisors, LLC
Phone: (617) 308-4306
mmoyer@lifesciadvisors.com

Media Contact:
Madelin Hawtin
LifeSci Communications
mhawtin@lifescicomms.com

Source: DiaMedica Therapeutics Inc.

Key Terms

pharmacodynamic medical

Pharmacodynamic describes how a drug acts on the body — the biological effects it produces, how strong those effects are, and how long they last. For investors, pharmacodynamic data show whether a treatment actually works and at what dose, shaping expectations about a drug’s safety, effectiveness, regulatory success and market potential; think of it like testing how well a key turns a lock and whether it reliably opens the door.

open-label medical

Open-label describes a situation where everyone involved in a study or process knows the full details, such as who is receiving a treatment or intervention. For investors, understanding whether a project or product is open-label helps gauge the level of transparency and potential biases, influencing trust and decision-making. It’s like knowing whether a test or experiment is conducted openly or behind closed doors.

single-arm medical

A single-arm study is a clinical trial that gives all participants the same treatment and does not include a separate comparison group or placebo. Think of it like testing a new recipe by serving it to diners without offering a control dish — you can see how people respond, but you can’t directly compare results to another option. For investors, single-arm trials can speed development and reduce cost but leave more uncertainty about how a treatment stacks up against existing therapies and how regulators will view the evidence.

placental insufficiency medical

Placental insufficiency is a medical condition in pregnancy where the placenta fails to deliver adequate oxygen and nutrients to the fetus. It usually results from poor blood flow through the placenta or abnormal placental development and can lead to slow fetal growth, low amniotic fluid, abnormal fetal heart-rate patterns, or preterm delivery; clinicians evaluate it using fetal growth measurements, Doppler ultrasound of placental and fetal blood flow, and monitoring of fetal well‑being. The term describes a functional problem with the placenta rather than a single specific cause, so management and prognosis depend on severity, gestational age, and the underlying reason.

serine protease medical

An enzyme that cuts peptide bonds in proteins using a serine amino acid residue in its active site to perform the chemical reaction; the serine’s reactive hydroxyl group acts as a nucleophile that attacks the bond between amino acids. Serine proteases vary in substrate preference and biological role—examples include digestive enzymes and proteases that drive blood clotting, complement and other activation cascades—and their activity can be regulated or blocked by specific inhibitors that bind the active site or nearby regions.

uteroplacental blood flow medical

The volume of maternal blood delivered to and circulated through the placenta and the uterine tissues that support it, carrying oxygen and nutrients from the mother to the fetus and removing fetal waste. It is determined by maternal blood pressure and cardiac output, the resistance of the uterine and placental blood vessels, and the structure of the placenta; clinicians assess it indirectly with measures such as uterine and umbilical artery Doppler flow, and reduced uteroplacental blood flow impairs oxygen and nutrient transfer to the fetus.